Moreover, neutralization of CCL2 by anti-CCL2 in preclinical researches attenuated tumor burden and improved tumor immune microenvironment by impairing Th2 immunity and abrogating infiltration of TAMs 72, 73. The gene discussed is CCL2; the disease is neoplasm.